You have 9 free searches left this month | for more free features.

stage II salivary gland cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)

Recruiting
  • Salivary Gland Carcinoma
  • Chicago, Illinois
  • +6 more
Sep 22, 2022

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +5 more
  • Pembrolizumab
  • Pemetrexed Disodium
  • Scottsdale, Arizona
  • +2 more
Mar 15, 2022

Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2022

Caregiver, Malignant Head and Neck Tumor, Paranasal Sinus Squamous Cell Carcinoma Trial in Winston-Salem (Communication

Completed
  • Caregiver
  • +37 more
  • Communication Intervention
  • +5 more
  • Winston-Salem, North Carolina
    Comprehensive Cancer Center of Wake Forest University
Dec 14, 2022

Gland, Salivary Gland Cancers Trial in Houston (Sacituzumab Govitecan)

Not yet recruiting
  • Gland
  • Salivary Gland Cancers
  • Sacituzumab Govitecan
  • Houston, Texas
    M D Anderson Cancer Center
May 22, 2023

Advanced Salivary Gland Carcinoma Trial in Shanghai (SHR-A1811, SHR 3680 + leuprolide, SHR-A1921)

Not yet recruiting
  • Advanced Salivary Gland Carcinoma
  • Shanghai, China
    Dongmei Ji
Jun 21, 2023

GENE EXPRESSION PROFILING IN A VALIDATION COHORT OF LOCALLY

Not yet recruiting
  • Salivary Gland Cancer
  • Observation
  • (no location specified)
Oct 13, 2023

Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial

Not yet recruiting
  • Locally Advanced Salivary Gland Carcinoma
  • +3 more
  • Biopsy
  • +3 more
  • (no location specified)
Jan 10, 2023

Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma Trial in Nijmegen (Lutetium-177-PSMA-I&T)

Recruiting
  • Salivary Gland Cancer
  • +2 more
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Oct 27, 2022

Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination

Not yet recruiting
  • Salivary Gland Cancer
  • vedicitumomab (Edisil, RC48)
  • +3 more
  • (no location specified)
Jun 9, 2023

Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,

Recruiting
  • Salivary Gland Cancer
  • HER2 Gene Mutation
  • Ado-trastuzumab (T) emtansine (T-DM1)
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 2, 2023

PSMA-PET Imaging of Salivary Gland Tumours and Other Rare

Recruiting
  • Salivary Gland Tumor
  • Rare Malignant Neoplasm
  • 68-Ga PSMA PET scan
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 11, 2022

Salivary Gland Tumors Trial in Beijing (RC48-ADC)

Recruiting
  • Salivary Gland Tumors
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 28, 2022

Salivary Gland Cancer Trial in Japan (Darolutamide, Goserelin)

Recruiting
  • Salivary Gland Cancer
  • Nagoya, Aichi, Japan
  • +11 more
Jan 21, 2023

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

Recruiting
  • Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2023

High-grade Salivary Gland Carcinoma Trial in Seoul (nivolumab, docetaxel, cisplatin Group)

Recruiting
  • High-grade Salivary Gland Carcinoma
  • nivolumab, docetaxel, cisplatin Group
  • Seoul, Korea, Republic of
    Department of Medicine, Samsung Medical Center, Sungkyunkwan Uni
Feb 3, 2023

Salivary Gland Cancer, Salivary Gland Tumors Trial in Novi Sad (Surgical intervention with or without postoperative adjuvant

Completed
  • Salivary Gland Cancer
  • Salivary Gland Neoplasms
  • Surgical intervention with or without postoperative adjuvant therapy
  • Novi Sad, Serbia
    Clinic for maxillofacial surgery Clinical center of Vojvodina
May 22, 2022

Xerostomia Due to Hyposecretion of Salivary Gland Trial in Cairo (Chamomile, Saline mouthwash)

Completed
  • Xerostomia Due to Hyposecretion of Salivary Gland
  • Chamomile
  • Saline mouthwash
  • Cairo, Egypt
    Ain Shams University
Nov 1, 2023

Malignant Salivary Gland Cancer, Salivary Gland Cancer Trial in Tampa, Chicago, Ann Arbor (APG-115, Carboplatin)

Recruiting
  • Malignant Salivary Gland Cancer
  • Salivary Gland Cancer
  • Tampa, Florida
  • +2 more
Feb 10, 2022

Adenoid Cystic Carcinoma, Salivary Gland Cancer Trial in United States (Lenvatinib, Pembrolizumab)

Recruiting
  • Adenoid Cystic Carcinoma
  • Salivary Gland Cancer
  • Miami, Florida
  • +7 more
Oct 26, 2022

Salivary Gland Carcinoma, Metastatic Cancer, Recurrent Cancer Trial in France (Nivolumab)

Completed
  • Salivary Gland Carcinoma
  • +2 more
  • Bordeaux, France
  • +10 more
Jan 10, 2022

Thyroid Cancer, Salivary Gland Cancer Trial in Chicago (Pembrolizumab, Docetaxel)

Recruiting
  • Thyroid Cancer
  • Salivary Gland Cancer
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Apr 13, 2022

Head Neck Cancer Trial in Groningen (Submandibular Gland Stem Cell Transplantation)

Recruiting
  • Head and Neck Cancer
  • Submandibular Gland Stem Cell Transplantation
  • Groningen, Netherlands
    UMCG
May 24, 2022

Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer Trial in Boston (9-ING-41, Carboplatin)

Withdrawn
  • Salivary Gland Carcinoma
  • +3 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Feb 5, 2022